Master Regulators of Epithelial-Mesenchymal Transition and WNT Signaling Pathways in Juvenile Nasopharyngeal Angiofibromas

Calanca, Naiade; Binato, Sara Martoreli Silveira; Silva, Sabrina Daniela da; Brentani, Helena; Sennes, Luiz Ubirajara; Pinto, Clóvis Antônio Lopes; Domingues, Maria Aparecida Custódio; Fonseca-Alves, Carlos Eduardo; Rainho, Cláudia Aparecida; Rogatto, Sílvia Regina

doi:10.3390/biomedicines9091258

Cited by 3 publications

(1 citation statement)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last decade, several studies described the involvement of specific genes and signaling pathways, such as Wnt, in JA progression [46]. In particular, Wnt5B, a member of the Wnt family, is overexpressed in JA [47]. Of note, CK2 acts as a positive regulator of Wnt signaling [48] and several studies have already suggested that pharmacological CK2 inhibition may be a promising therapeutic approach for the treatment of tumors with high Wnt activity, such as chronic lymphocytic leukemia and B-cell lymphomas [49,50].…”

Section: Discussionmentioning

confidence: 99%

Inhibition of CK2 Reduces NG2 Expression in Juvenile Angiofibroma

et al. 2022

View full text Add to dashboard Cite

Juvenile angiofibroma (JA) is a rare fibrovascular neoplasm predominately found within the posterior nasal cavity of adolescent males. JA expresses the proteoglycan nerve–glial antigen (NG)2, which crucially determines the migratory capacity of distinct cancer cells. Moreover, it is known that the protein kinase CK2 regulates NG2 gene expression. Therefore, in the present study, we analyzed whether the inhibition of CK2 suppresses NG2-dependent JA cell proliferation and migration. For this purpose, we assessed the expression of NG2 and CK2 in patient-derived JA tissue samples, as well as in patient-derived JA cell cultures by Western blot, immunohistochemistry, flow cytometry and quantitative real-time PCR. The mitochondrial activity, proliferation and migratory capacity of the JA cells were determined by water-soluble tetrazolium (WST)-1, 5-bromo-2′-deoxyuridine (BrdU) and collagen sprouting assays. We found that NG2 and CK2 were expressed in both the JA tissue samples and cell cultures. The treatment of the JA cells with the two CK2 inhibitors, CX-4945 and SGC-CK2-1, significantly reduced NG2 gene and protein expression when compared to the vehicle-treated cells. In addition, the loss of CK2 activity suppressed the JA cell proliferation and migration. These findings indicate that the inhibition of CK2 may represent a promising therapeutic approach for the treatment of NG2-expressing JA.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of CK2 Reduces NG2 Expression in Juvenile Angiofibroma

et al. 2022

View full text Add to dashboard Cite

show abstract

Integrated Molecular and Histological Insights for Targeted Therapies in Mesenchymal Sinonasal Tract Tumors

Hoch,

Knoedler,

Knoedler

et al. 2024

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose of Review This review aims to provide a comprehensive overview of mesenchymal sinonasal tract tumors (STTs), a distinct subset of STTs. Despite their rarity, mesenchymal STTs represent a unique clinical challenge, characterized by their rarity, often slow progression, and frequently subtle or overlooked symptoms. The complex anatomy of the sinonasal area, which includes critical structures such as the orbit, brain, and cranial nerves, further complicates surgical treatment options. This underscores an urgent need for more advanced and specialized therapeutic approaches. Recent Findings Advancements in molecular diagnostics, particularly in next-generation sequencing, have significantly enhanced our understanding of STTs. Consequently, the World Health Organization has updated its tumor classification to better reflect the distinct histological and molecular profiles of these tumors, as well as to categorize mesenchymal STTs with greater accuracy. The growing understanding of the molecular characteristics of mesenchymal STTs opens new possibilities for targeted therapeutic interventions, marking a significant shift in treatment paradigms. Summary This review article concentrates on mesenchymal STTs, specifically addressing sinonasal tract angiofibroma, sinonasal glomangiopericytoma, biphenotypic sinonasal sarcoma, and skull base chordoma. These entities are marked by unique histopathological and molecular features, which challenge conventional treatment approaches and simultaneously open avenues for novel targeted therapies. Our discussion is geared towards delineating the molecular underpinnings of mesenchymal STTs, with the objective of enhancing therapeutic strategies and addressing the existing shortcomings in the management of these intricate tumors.

show abstract

Preoperative Transarterial Embolization of Advanced Juvenile Nasopharyngeal Angiofibroma Using n-Butyl Cyanoacrylate: Case-Control Comparison with Microspheres

Liu

Ren

et al. 2023

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

Master Regulators of Epithelial-Mesenchymal Transition and WNT Signaling Pathways in Juvenile Nasopharyngeal Angiofibromas

Cited by 3 publications

References 71 publications

Inhibition of CK2 Reduces NG2 Expression in Juvenile Angiofibroma

Inhibition of CK2 Reduces NG2 Expression in Juvenile Angiofibroma

Integrated Molecular and Histological Insights for Targeted Therapies in Mesenchymal Sinonasal Tract Tumors

Preoperative Transarterial Embolization of Advanced Juvenile Nasopharyngeal Angiofibroma Using n-Butyl Cyanoacrylate: Case-Control Comparison with Microspheres

Contact Info

Product

Resources

About